PDCD1 and hepatocellular carcinoma: Activation of β‐catenin has been associated with immune evasion and resistance to anti‐PD‐1 therapy in mouse HCC models.[16] To further assess the effectiveness of BCG in treating HCC, β‐catenin‐positive HCC models were used.